Abstract

Development of NX211 (liposomal lurtotecan) is that liposomal encapsulation will prolong the plasma half life of lurtotecan in human subjects, resulting in prolonged tumor exposure, enhanced efficacy and an improved therapeutic index. Based upon pre-clinical data, it is believed that liposomal encapsulation may be more effective than free lurtotecan. Also, neutrophil and platelet counts on Day 8 will be satisfactory to proceed w/administration of the second dose of the cycle. SPECIFIC ENDPOINTS: 1) To evaluate the safety and tolerability of NX211 2) To establish the Dose Limiting Toxicities (DLT) of NX211 and to identify the recommended dose for Phase II studies 3) To evaluated the pharmacokinetic profile of NX211 4) To evaluated any anti-tumor activity in a preliminary manner 5) To assess, for descriptive pruposes, NX211 concentrations in tissue samples (tumor and adjacent normal tissue) in selected patients 6) A secondary objective is to determine whether or not NX211 crosses the blood-brain barrier -to evaluate the safety and tolerability.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000095-40
Application #
6409630
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1977-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
40
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203

  Publications

Kaltenbach, Karol; O'Grady, Kevin E; Heil, Sarah H et al. (2018) Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. Drug Alcohol Depend 185:40-49
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Gilchuk, Pavlo; Knight, Frances C; Wilson, John T et al. (2017) Eliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with ?-Galactosylceramide: Theory, Practice, and Protocols. Methods Mol Biol 1494:321-352
Sebag, Sara C; Koval, Olha M; Paschke, John D et al. (2017) Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma. JCI Insight 2:e88297
Laird, Chris; Burdorf, Lars; Pierson 3rd, Richard N (2016) Lung xenotransplantation: a review. Curr Opin Organ Transplant 21:272-8
Chung, C P; Ormseth, M J; Connelly, M A et al. (2016) GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus. Lupus 25:296-300
Towse, Theodore F; Childs, Benjamin T; Sabin, Shea A et al. (2016) Comparison of muscle BOLD responses to arterial occlusion at 3 and 7 Tesla. Magn Reson Med 75:1333-40
Joy, Nino G; Mikeladze, Maia; Younk, Lisa M et al. (2016) Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes. Metabolism 65:1695-1705
Gilchuk, Pavlo; Hill, Timothy M; Guy, Clifford et al. (2016) A Distinct Lung-Interstitium-Resident Memory CD8(+) T Cell Subset Confers Enhanced Protection to Lower Respiratory Tract Infection. Cell Rep 16:1800-9
Jones, Hendrée E; Seashore, Carl; Johnson, Elisabeth et al. (2016) Measurement of neonatal abstinence syndrome: Evaluation of short forms. J Opioid Manag 12:19-23

Showing the most recent 10 out of 515 publications